Queensland Centre for Gynaecological Cancer
18
4
5
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
28%
5 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection
Role: lead
A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer
Role: lead
NODE (groiN ultrasOunD cancEr)
Role: lead
Sentinel Node Biopsy in Endometrial Cancer
Role: lead
SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)
Role: lead
Improving the Treatment for Women With Early Stage Cancer of the Uterus
Role: lead
Laparoscopic Approach to Cervical Cancer
Role: lead
The Implementation of MinimAlly Invasive Hysterectomy Trial
Role: lead
Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
Role: lead
Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer
Role: lead
Telephone Follow-up After Treatment for Endometrial Cancer
Role: lead
The Effects of the Endocrine System on Endometrial Cancer
Role: lead
Barriers for the Uptake of LaparoScopic Hysterectomy
Role: lead
Laparoscopic Approach to Cancer of the Endometrium
Role: lead
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Role: lead
Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer
Role: lead
Uterine Papillary Serous Cancer (UPSC) Trial
Role: lead
Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery
Role: lead
All 18 trials loaded